在免疫瘤学中保护内分泌轴:GLP-1受体激活剂作为结直肠癌中宿主导调节剂
Samira Saghafi1, Mohammad Ali Yaghoubi2, Hossein Safarpour3
1Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|January 7, 2026
概括
对结直肠癌 (CRC) 的免疫检查点抑制剂 (ICI) 可以导致持久的内分泌损伤. 类似葡萄糖-1受体激动剂 (GLP-1RAs) 可以防止这种毒性,同时保持抗瘤作用.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 免疫检查点抑制剂 (ICI) 改善了结直肠癌 (CRC) 的结果,特别是在微卫星不稳定性高 (MSI-H) 和不匹配修复缺陷 (dMMR) 瘤中.
- 然而,ICI经常导致不可逆转的内分泌免疫相关不良事件 (irAEs),包括甲状腺炎,低血压炎和糖尿病,需要终身激素替代.
- 目前对内分泌IRAE的管理是反应性的,缺乏预防策略.
研究的目的:
- 探索类似葡萄糖-1受体激动剂 (GLP-1RAs) 在预防或减轻CRC中ICI诱导的内分泌毒性方面的潜力.
- 研究GLP-1RAs在CRC和内分泌自身免疫的背景下对免疫调节,代谢和微生物组改变的影响.
- 提出一个翻译研究策略,将GLP-1RA整合到CRC治疗范式中.
主要方法:
- 对ICI诱导的内分泌损伤和GLP-1RA免疫生物学的当前知识的综合.
- 开发一种机制框架,将GLP-1RA与内分泌IRA和CRC中的抗瘤免疫联系起来.
- 关于翻译路线图的建议,包括药理流行病学,生物标志物分层和临床试验.
主要成果:
- GLP-1RAs调节炎症,免疫代谢和肠道微生物群,汇聚在与内分泌irAEs相关的机制上.
- 临床前和流行病学数据表明GLP-1RAs可能会降低癌症发生率并改变瘤免疫力.
- GLP-1RAs在减轻内分泌自身免疫力方面具有潜在的双重效用,同时保持或增强抗瘤功效.
结论:
- GLP-1RAs代表了一种有前途的宿主导疗法,用于控制ICI治疗的CRC患者的内分泌IRAE.
- 需要仔细整合,考虑到潜在的风险,如癌症缓解症是必要的.
- GLP-1RAs可能会将免疫瘤学的重点转向保护生存率和内分泌健康,作为整体癌症治疗的终点.
更多相关视频
08:42Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
2.0K
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
1.7K
相关概念视频
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
